Literature DB >> 10393360

Expression of c-erbB-2 oncoprotein in gastric carcinoma: correlation with histopathologic characteristics and analysis of Ki-67.

A Dursun1, A Poyraz, B Celik, G Akyol.   

Abstract

Amplification and overexpression of the c-erbB-2 gene has been demonstrated in several tumors and thought to be important determinants of biologic behaviors of carcinomas. In this study, correlation between c-erbB-2 expression und histopathologic parameters, including proliferative activity of gastric carcinomas was evaluated. Paraffin-embedded tissue sections from 62 patients who underwent curative resection of gastric carcinoma were analyzed immunohistochemically for the expression of c-erbB-2 and Ki-67. Strong membrane staining for c-erbB-2 was detected in 11 of 62 gastric carcinomas (17,7%) and no positive reaction was evident in noncancerous tissue. The incidence of c-erbB-2 positivity in intestinal type carcinomas (24,3%) was higher than that of diffuse type carcinomas (4,76%). Positive staining for c-erbB-2 was present in one of the 9 (11,1%) early gastric carcinomas and 10 of 53 (18, 8%) advanced gastric carcinomas. However, no statistically significant relationships were found between c-erbB-2 expression and histopathologic type, depth on invasion, the tumor size or lymph node metastases. Among the metastatic lymph nodes, 3 were positively stained with c-erbB-2 whereas the primary tumors of two cases had been found to be negative. Additionally, no correlation was found between c-erbB-2 reactivity and proliferative activity of carcinoma cells. The results suggest that expression of c-erbB-2 protein may occur selectively in intestinal type of gastric carcinomas. However, c-erbB-2 expression is not a reliable marker of malignant potential in gastric carcinomas.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10393360     DOI: 10.1053/paor.1999.0171

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  18 in total

1.  THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION.

Authors:  P LAUREN
Journal:  Acta Pathol Microbiol Scand       Date:  1965

2.  c-erbB-2 oncogene product staining in gastric adenocarcinoma. An immunohistochemical study.

Authors:  V G Falck; W J Gullick
Journal:  J Pathol       Date:  1989-10       Impact factor: 7.996

3.  Expression of c-erbB-2 oncoprotein in gastric carcinoma. Immunoreactivity for c-erbB-2 protein is an independent indicator of poor short-term prognosis in patients with gastric carcinoma.

Authors:  Y Yonemura; I Ninomiya; S Ohoyama; H Kimura; A Yamaguchi; S Fushida; T Kosaka; K Miwa; I Miyazaki; Y Endou
Journal:  Cancer       Date:  1991-06-01       Impact factor: 6.860

4.  Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor.

Authors:  T Yamamoto; S Ikawa; T Akiyama; K Semba; N Nomura; N Miyajima; T Saito; K Toyoshima
Journal:  Nature       Date:  1986 Jan 16-22       Impact factor: 49.962

5.  An immunohistochemical study of c-erbB-2 protein in gastric carcinomas and lymph-node metastases: is the c-erbB-2 protein really a prognostic indicator?

Authors:  T Ohguri; Y Sato; W Koizumi; K Saigenji; T Kameya
Journal:  Int J Cancer       Date:  1993-01-02       Impact factor: 7.396

6.  Expression of ERBB2 in human gastric carcinomas: relationship between p185ERBB2 expression and the gene amplification.

Authors:  T Kameda; W Yasui; K Yoshida; T Tsujino; H Nakayama; M Ito; H Ito; E Tahara
Journal:  Cancer Res       Date:  1990-12-15       Impact factor: 12.701

7.  Gastric carcinoma: recent issues in prognostic factors.

Authors:  B F Chen; A J Marrogi; S M Freeman; S Clejan
Journal:  J La State Med Soc       Date:  1995-04

8.  Expression of c-erbB-2 oncogene product in Barrett's adenocarcinoma: pathological and prognostic correlations.

Authors:  J F Fléjou; F Paraf; F Muzeau; F Fékété; D Hénin; S Jothy; F Potet
Journal:  J Clin Pathol       Date:  1994-01       Impact factor: 3.411

9.  erbB-2 expression in well-differentiated adenocarcinoma of the stomach predicts shorter survival after curative resection.

Authors:  K Motojima; J Furui; N Kohara; K Izawa; T Kanematsu; H Shiku
Journal:  Surgery       Date:  1994-03       Impact factor: 3.982

10.  Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients.

Authors:  S Uchino; H Tsuda; K Maruyama; T Kinoshita; M Sasako; T Saito; M Kobayashi; S Hirohashi
Journal:  Cancer       Date:  1993-12-01       Impact factor: 6.860

View more
  8 in total

1.  Extremely well-differentiated adenocarcinoma of the stomach: clinicopathological and immunohistochemical features.

Authors:  Takashi Yao; Takashi Utsunomiya; Masafumi Oya; Kenichi Nishiyama; Masazumi Tsuneyoshi
Journal:  World J Gastroenterol       Date:  2006-04-28       Impact factor: 5.742

2.  Expression profile as predictor of relapse after adjuvant treatment in gastric cancer.

Authors:  María Sereno; Javier De Castro; Paloma Cejas; Miguel Angel García-Cabezas; Cristóbal Belda; Enrique Casado; Jaime Feliu; César Gómez; Miriam López; Manuel González Barón
Journal:  J Gastrointest Cancer       Date:  2012-06

3.  Mast cell density and the context of clinicopathological parameters and expression of p185, estrogen receptor, and proliferating cell nuclear antigen in gastric carcinoma.

Authors:  Ying-An Jiang; You-Yuan Zhang; He-Sheng Luo; Shou-Fu Xing
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

4.  Investigation of HER-2 codon 655 single nucleotide polymorphism frequency and c-ErbB-2 protein expression alterations in gastric cancer patients.

Authors:  N-Lale Satiroglu-Tufan; Ferda Bir; Nese Calli-Demirkan
Journal:  World J Gastroenterol       Date:  2006-05-28       Impact factor: 5.742

5.  Expression of p53, c-erbB-2 and Ki67 in intestinal metaplasia and gastric carcinoma.

Authors:  Yao Zheng; Lin Wang; Jian-Ping Zhang; Jing-Yan Yang; Zhu-Mei Zhao; Xiao-Ying Zhang
Journal:  World J Gastroenterol       Date:  2010-01-21       Impact factor: 5.742

6.  Prognostic significance of c-erbB2 overexpression in patients with metastatic gastric cancer.

Authors:  Muharrem Bayrak; Omer Fatih Olmez; Ender Kurt; Erdem Cubukcu; Turkkan Evrensel; Ozkan Kanat; Osman Manavoglu
Journal:  Clin Transl Oncol       Date:  2012-08-22       Impact factor: 3.405

7.  Epidemiologic Study of Human Epidermal Growth Factor Receptor 2 Expression in Advanced/Metastatic Gastric Cancer: an Assessment of Human Epidermal Growth Factor Receptor 2 Status in Tumor Tissue Samples of Gastric and Gastro-Esophageal Junction Cancer.

Authors:  Kyung Won Seo; Taeyong Jeon; Sewon Kim; Sung Soo Kim; Kwanghee Kim; Byoung-Jo Suh; Sunhwi Hwang; SeongHee Choi; Seungwan Ryu; Jae Seok Min; Young-Joon Lee; Ye Seob Jee; Hyeondong Chae; Doo Hyun Yang; Sang Ho Lee
Journal:  J Gastric Cancer       Date:  2017-03-17       Impact factor: 3.720

Review 8.  The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature.

Authors:  Yu-Ying Lei; Jin-Yu Huang; Qiong-Rui Zhao; Nan Jiang; Hui-Mian Xu; Zhen-Ning Wang; Hai-Qing Li; Shi-Bo Zhang; Zhe Sun
Journal:  World J Surg Oncol       Date:  2017-03-21       Impact factor: 2.754

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.